Piramal Pharma Ltd Share Price

₹166.50 -1.70 (-1.01%) BSE
as updated on 18-Dec-2025 16:59 | Sector - Healthcare

Day Range

  • Day's Low:165.05
  • Day's High:168.50

  • 52 Week Low166.50
  • 52 Week High273.20

Piramal Pharma Ltd's key Fundamentals

Market Cap ₹22,358 Cr.
P/E Ratio 31.7
TTM EPS 5.3
P/B Ratio 2.89
ROE 9.79
Debt to Equity 0.17
Face Value 10
BVPS 58.3
3 Year Sales Growth 16.53%

Piramal Pharma Ltd's Share Price Returns

1 Day -1.01%
1 Week -3.10%
1 Month -13.30%
3 Months -20.10%
6 Months -14.60%
1 Years -37.10%
3 Years 33.40%
5 Years 0.00%
10 Years 0%

Financial Ratio Analysis

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

Check our DeciZen before investing

Check Stock Quality
Check Stock Valuation
Check Price Trend

Piramal Pharma Ltd Shareholding Pattern

Promoters

(34.86%)

Institutions

(45.16%)

Non-Institutions

(19.98%)

Pledged shares as % of Promoter's holding (%)

(0.00%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Balance Sheet

(All Figures are in Crores.)

Profit And Loss

(All Figures in Cr. Adjusted EPS in Rs.)

Cash Flow

(All Figures are in Crores.)

About Piramal Pharma Ltd

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.

Business area of the company

The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products.

Read More Read Less
Read More Read Less

Investment related blogs

Day Range

  • Day's Low: 165.05
  • Day's High: 168.50

  • 52 Week Low166.50
  • 52 Week High273.20

Piramal Pharma Ltd's key Fundamentals

Market Cap ₹22,358 Cr.
P/E Ratio 31.7
TTM EPS 5.3
P/B Ratio 2.89
ROE 9.79
Debt to Equity 0.17
Face Value 10
BVPS 58.3
3 Year Sales Growth 16.53%

Piramal Pharma Ltd's Share Price Returns

1 Day -1.01%
1 Week -3.10%
1 Month -13.30%
3 Months -20.10%
6 Months -14.60%
1 Years -37.10%
3 Years 33.40%
5 Years 0.00%
10 Years 0%

Investment related blogs

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×